Brilinta No Better Than Aspirin In Stroke Trial
This article was originally published in Scrip
Executive Summary
Topline data from the SOCRATES trial of Brilinta (Brilique; ticagrelor) provided more ammunition for those pushing for AstraZeneca's CEO Pascal Soriot to have his pay linked to performance.